Daiichi Sankyo Company and Ranbaxy Laboratories have announced plans to combine business operations in Thailand.
Both the companies plan to integrate the management of Daiichi Sankyo (Thailand) (DSTH) and Ranbaxy Unichem (RUCL), the Thailand subsidiary of Daiichi Sankyo and Ranbaxy's Thailand subsidiary respectively.
Present head of DSTH, Suthas Thongprasert, will be the new representative of the proposed integrated entity that is expected to start business on 1 April 2013.
Companies anticipate leveraging and maximizing the synergies of the Hybrid Business Model.
The planned integration of operations is expected to be mutually beneficial to Ranbaxy and Daiichi Sankyo.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/daiichi-sankyo-ranbaxy-to-combine-thailand-business-operations-170113
